Prenetics Global (PRE, Financial) experienced significant stock volatility with a sharp decline of 8.96%. The stock is currently priced at $4.03 per share with a trading volume of 674 shares and a turnover rate of 0.01%. Recent financial data reveals revenue of $5.94 million and a net loss of $10.80 million, translating to an earnings per share (EPS) of -$0.88. The company's gross profit stands at $2.03 million with a price-to-earnings (P/E) ratio of -0.98. Currently, no institutional ratings are available for the stock.
Within the life sciences sector, where Prenetics Global operates, the overall market experienced a slight decline of 0.36%. Notable performers include Inotiv, Inc., Charles River Laboratories, and Medpace Holdings, Inc. which saw significant gains. Additionally, Endra Life Sciences Inc., Ispecimen Inc., and Precision Science showed notable trading activity, with turnover rates of 24.28%, 7.88%, and 5.66% respectively. Endra Life Sciences Inc., Inotiv, Inc., and T2 Biosystems, Inc. exhibited considerable price fluctuations at 32.67%, 29.92%, and 19.84% respectively.
Prenetics Global Ltd is engaged in diagnostics and genetic testing. The company aims to enhance global health accessibility by providing comprehensive preventive, diagnostic, and personalized care services. Their operations span nine regions, including the UK, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic tests and early colorectal cancer screening, offers COVID-19 testing, and provides rapid point-of-care and at-home diagnostic tests along with medical genetic testing.
